Generation Bio Co
GBIO4.580USD
+0.370+8.79%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
306.90MCap. mercado
PérdidaP/E TTM
Más Datos de Generation Bio Co Compañía
Generation Bio Co. is a biotechnology company. The Company is innovating non-viral genetic medicines to provide durable, redosable treatments for hundreds of millions of patients living with rare and prevalent diseases. The Company is developing two distinct and complementary platforms: a potent, highly selective cell-targeted lipid nanoparticle (ctLNP) delivery system and a novel immune-quiet DNA (iqDNA) cargo produced by a scalable capsid-free manufacturing process that uses proprietary cell-free rapid enzymatic synthesis (RES). The Company is advancing a portfolio of programs guided by the potent and highly selective delivery of messenger ribonucleic acid (mRNA) and/or iqDNA using its ctLNP delivery system to target T cells, hematopoietic stem cells (HSCs), and hepatocytes, and intend to expand to additional tissues and cell types. Its work in T cells focuses on in vivo reprogramming of this cell type to treat cancer and autoimmune diseases.
Información de la empresa
Símbolo de cotizaciónGBIO
Nombre de la empresaGeneration Bio Co
Fecha de salida a bolsaJun 12, 2020
Director ejecutivoDr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
Número de empleados115
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 12
Dirección301 Binney Street
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142
Teléfono18575295908
Sitio Webhttps://generationbio.com/
Símbolo de cotizaciónGBIO
Fecha de salida a bolsaJun 12, 2020
Director ejecutivoDr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
Dr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
185.48K
+0.20%
Dr. Anthony G. Quinn, M.D., Ph.D.
Dr. Anthony G. Quinn, M.D., Ph.D.
Independent Director
Independent Director
37.21K
--
Mr. Gustav A. Christensen
Mr. Gustav A. Christensen
Independent Director
Independent Director
13.14K
--
Dr. Phillip Samayoa, Ph.D.
Dr. Phillip Samayoa, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
12.93K
+0.63%
Ms. Yalonda Howze, J.D.
Ms. Yalonda Howze, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
6.70K
+3.67%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
4.75K
--
Ms. Dannielle Appelhans
Ms. Dannielle Appelhans
Independent Director
Independent Director
2.00K
+150.00%
Mr. Kevin John Conway
Mr. Kevin John Conway
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
1.83K
+2.35%
Mr. Ronald Harold Wilfred (Ron) Cooper
Mr. Ronald Harold Wilfred (Ron) Cooper
Independent Director
Independent Director
950.00
--
Mr. Jason Rhodes
Mr. Jason Rhodes
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
Dr. Cameron Geoffrey (Geoff) Mcdonough, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
185.48K
+0.20%
Dr. Anthony G. Quinn, M.D., Ph.D.
Dr. Anthony G. Quinn, M.D., Ph.D.
Independent Director
Independent Director
37.21K
--
Mr. Gustav A. Christensen
Mr. Gustav A. Christensen
Independent Director
Independent Director
13.14K
--
Dr. Phillip Samayoa, Ph.D.
Dr. Phillip Samayoa, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
12.93K
+0.63%
Ms. Yalonda Howze, J.D.
Ms. Yalonda Howze, J.D.
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
6.70K
+3.67%
Dr. Catherine Stehman-Breen, M.D.
Dr. Catherine Stehman-Breen, M.D.
Independent Director
Independent Director
4.75K
--
Desglose de ingresos
FY2024
FY2023
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
19.89M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
T. Rowe Price Associates, Inc.
13.25%
Atlas Venture
12.35%
Modernatx Inc
8.74%
Fidelity Management & Research Company LLC
7.09%
BlackRock Institutional Trust Company, N.A.
4.64%
Other
53.93%
Accionistas
Accionistas
Proporción
T. Rowe Price Associates, Inc.
13.25%
Atlas Venture
12.35%
Modernatx Inc
8.74%
Fidelity Management & Research Company LLC
7.09%
BlackRock Institutional Trust Company, N.A.
4.64%
Other
53.93%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
38.32%
Venture Capital
12.43%
Investment Advisor/Hedge Fund
9.30%
Corporation
8.74%
Hedge Fund
6.59%
Individual Investor
5.64%
Research Firm
5.05%
Family Office
0.13%
Bank and Trust
0.09%
Other
13.72%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
204
5.77M
86.15%
-1.71M
2025Q1
216
58.42M
87.25%
-16.87M
2024Q4
239
64.26M
96.22%
-10.38M
2024Q3
252
65.74M
98.51%
-9.46M
2024Q2
257
65.96M
99.11%
-9.63M
2024Q1
256
65.28M
99.25%
-2.56M
2023Q4
262
62.66M
95.79%
-3.14M
2023Q3
260
66.58M
101.93%
-550.54K
2023Q2
272
66.62M
102.34%
-297.13K
2023Q1
283
66.66M
111.77%
+650.55K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
T. Rowe Price Associates, Inc.
8.88M
13.25%
-217.22K
-2.39%
Mar 31, 2025
Atlas Venture
8.28M
12.35%
--
--
Mar 31, 2025
Modernatx Inc
5.86M
8.74%
--
--
Apr 07, 2025
Fidelity Management & Research Company LLC
4.75M
7.09%
+126.37K
+2.73%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.11M
4.64%
-49.92K
-1.58%
Mar 31, 2025
Invus Public Equities Advisors, LLC
2.97M
4.43%
-13.81K
-0.46%
Mar 31, 2025
The Vanguard Group, Inc.
2.62M
3.91%
-22.29K
-0.84%
Mar 31, 2025
Baker Bros. Advisors LP
1.94M
2.9%
--
--
Mar 31, 2025
Renaissance Technologies LLC
1.88M
2.81%
+917.71K
+95.30%
Mar 31, 2025
McDonough (Cameron Geoffrey)
1.85M
2.76%
+15.31K
+0.83%
Apr 15, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
Proshares Ultra Russell 2000
0%
Global X Russell 2000 Covered Call ETF
0%
iShares Micro-Cap ETF
0%
iShares Russell 2000 ETF
0%
iShares Biotechnology ETF
0%
Avantis US Small Cap Equity ETF
0%
Fidelity Blue Chip Growth ETF
0%
Avantis US Equity ETF
0%
ProShares Ultra Nasdaq Biotechnology
0%
Invesco RAFI US 1500 Small-Mid ETF
0%
Ver más
Proshares Ultra Russell 2000
Proporción0%
Global X Russell 2000 Covered Call ETF
Proporción0%
iShares Micro-Cap ETF
Proporción0%
iShares Russell 2000 ETF
Proporción0%
iShares Biotechnology ETF
Proporción0%
Avantis US Small Cap Equity ETF
Proporción0%
Fidelity Blue Chip Growth ETF
Proporción0%
Avantis US Equity ETF
Proporción0%
ProShares Ultra Nasdaq Biotechnology
Proporción0%
Invesco RAFI US 1500 Small-Mid ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
